Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.
You may also be interested in...
Second Time's The Charm: Novartis' New Bid Lures Chiron
Chiron's vaccines unit will operate as a separate division while its biopharmaceuticals unit will merge with Novartis' pharmaceutical business.
Second Time's The Charm: Novartis' New Bid Lures Chiron
Chiron's vaccines unit will operate as a separate division while its biopharmaceuticals unit will merge with Novartis' pharmaceutical business.
Novartis Willing To “Walk Away” From Chiron Bid
Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.